Determination of fitness and therapeutic options in older patients with acute myeloid leukemia

por Cortes, Jorge E., Mehta, Priyanka
Publicado 2021

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia

por Swaminathan, Mahesh, Cortes, Jorge E.
Publicado 2023

Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health “All of Us” Research Program

por Coughlin, Steven S., Chen, Jie, Cortes, Jorge E.
Publicado 2021

Financial assistance programs for cancer patients

por Coughlin, Steven S., Dean, Lorraine T., Cortes, Jorge E.
Publicado 2021

Problems in living among breast cancer survivors

por Coughlin, Steven S., Ayyala, Deepak Nag, Cortes, Jorge E.
Publicado 2021

Addressing financial toxicity in oncology care

por Coughlin, Steven S., Moore, Justin Xavier, Cortes, Jorge E.
Publicado 2021

Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia

por Garrett, May, Knight, Beverly, Cortes, Jorge E., Deininger, Michael W.
Publicado 2023

Financial distress among breast cancer survivors

por Coughlin, Steven S., Ayyala, Deepak Nag, Tingen, Martha S., Cortes, Jorge E.
Publicado 2020

Eine klinische Perspektive auf die Behandlung von chronischer myeloischer Leukämie in der chronischen Phase

por García-Gutiérrez, Valentin, Breccia, Massimo, Jabbour, Elias, Mauro, Michael, Cortes, Jorge E.
Publicado 2023

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

por Lin, Swan, Shaik, Naveed, Chan, Geoffrey, Cortes, Jorge E., Ruiz-Garcia, Ana
Publicado 2020

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

por García-Gutiérrez, Valentin, Breccia, Massimo, Jabbour, Elias, Mauro, Michael, Cortes, Jorge E.
Publicado 2022

2008. Effective and Early Diagnosis of Pneumonia in Patients With Acute Leukemia in a Comprehensive Cancer Center: How Can We Improve the Microbiological Diagnosis?

por Sakurai, Aki, Bala-Hampton, Justin, Mulanovich, Victor E, Cortes, Jorge E, Adachi, Javier
Publicado 2018

Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review

por Miranda-Galvis, Marisol, Tjioe, Kellen C., Balas, E. Andrew, Agrawal, Gagan, Cortes, Jorge E.
Publicado 2023

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysi...

por Cortes, Jorge E., Lin, Tara L., Asubonteng, Kobby, Faderl, Stefan, Lancet, Jeffrey E., Prebet, Thomas
Publicado 2022

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

por Altman, Jessica K., Foran, James M., Pratz, Keith W., Trone, Denise, Cortes, Jorge E., Tallman, Martin S.
Publicado 2017

Pregnancy outcomes in patients treated with bosutinib

por Cortes, Jorge E, Gambacorti-Passerini, Carlo, Deininger, Michael, Abruzzese, Elisabetta, DeAnnuntis, Liza, Brümmendorf, Tim H
Publicado 2020

2211. Impact of Early Fiberoptic Bronchoscopy on Microbiological Diagnostic Rate and Clinical Outcomes of Pneumonia in Acute Leukemia Patients

por Sakurai, Aki, Bala-Hampton, Justin E, Mulanovich, Victor E, Wierda, William G, Cortes, Jorge E, Adachi, Javier
Publicado 2019

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

por Cortes, Jorge E., Lin, Tara L., Uy, Geoffrey L., Ryan, Robert J., Faderl, Stefan, Lancet, Jeffrey E.
Publicado 2021

Immunological Response to Sars-Cov-2 after Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients - a Prospective Study

por Miranda, Marisol, Kolhe, Ravindra, Bradshaw, Danielle, Farmaha, Jaspreet, Jones, Kimya, Singh, Harmanpreet, Vashisht, Ashutosh, Sahajpal, Nikhil, Cortes, Jorge E.
Publicado 2022

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leuke...

por Solem, Caitlyn T., Bell, Timothy J., Kwon, Youngmin, Cappelleri, Joseph C., Johnson, Courtney, Bhattacharyya, Helen, Hoang, Caroline J., Cortes, Jorge E.
Publicado 2020